Clinical outcomes for rectal carcinoid tumors according to a new (AJCC 7th edition) TNM staging system: A single institutional analysis of 122 patients1. Issue 8 (15th March 2013)

• Record Type: Journal Article
• Authors: Kim, Min Sung; Hur, Hyuk; Min, Byung Soh; Baik, Seung Hyuk; Lee, Kang Young; Kim, Nam Kyu
• Is Part Of: Journal of surgical oncology. Volume 107:Issue 8(2013:Jun. 15)
• Page Start: 835
• Page End: 841
• Publication Date: 2013-03-15
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23327
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>Background and Objectives</title> <p>This study aimed to describe clinical outcomes of rectal carcinoids according to the 7th American Joint Council on Cancer (AJCC) TNM staging system.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>Methods</title> <p>We retrospectively reviewed 122 patients who were treated for rectal carcinoids between 1995 and 2010.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>Results</title> <p>Among 122 patients, 81.2% (n = 99) were classified as stage I, 4.9% (n = 6) as stage II, 11.5% (n = 14) as stage III, and 2.5% (n = 3) as stage IV. Lymph node (LN) metastasis rates for pT1a, 1b, 2, and 3 stages were 1.2% (1/85), 16.7% (3/18), 0% (0/4) and 84.6% (11/13), respectively. The 5‐year overall survival (OS) rate was 88.4%. The 5‐year OS rates were estimated to be 100%, 80%, 51.4% and 0% for stage I, II, III, and IV, respectively (<italic>P</italic> < 0.001). The 5‐year disease‐free survival (DFS) rate was 82.3%. The 5‐year DFS rates were estimated to be 97.7%, 62.5%, 17.1%, and 0% for stages I, II, III, and IV, respectively (<italic>P</italic> < 0.001).</p> </sec> <sec id="abs1-4" sec-type="section"> <title>Conclusions</title> <p>Using the new TNM stage, we confirmed a prognostic difference in LN metastasis rates, OS, and DFS for rectal carcinoids. In clinical practice, the new TNM stage can be very useful for predicting prognosis. J. Surg. Oncol. 2013;107:835–841. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>